Which has stronger earnings and valuation, FBRX or COGT?

Forte Biosciences is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.65 N/A Cogent Biosciences N/A N/A -$328.94M -$2.16 N/A

Is FBRX or COGT more profitable?

Cogent Biosciences' return on equity of -84.47% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -94.82% -77.68% Cogent Biosciences N/A -84.47% -47.72%

Does the media prefer FBRX or COGT?

In the previous week, Cogent Biosciences had 3 more articles in the media than Forte Biosciences. MarketBeat recorded 11 mentions for Cogent Biosciences and 8 mentions for Forte Biosciences. Cogent Biosciences' average media sentiment score of 1.27 beat Forte Biosciences' score of 0.80 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MIRM or FBRX?

In the previous week, Mirum Pharmaceuticals had 10 more articles in the media than Forte Biosciences. MarketBeat recorded 18 mentions for Mirum Pharmaceuticals and 8 mentions for Forte Biosciences. Mirum Pharmaceuticals' average media sentiment score of 1.24 beat Forte Biosciences' score of 0.80 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 11 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Forte Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor FBRX or TVTX?

In the previous week, Forte Biosciences and Forte Biosciences both had 8 articles in the media. Travere Therapeutics' average media sentiment score of 1.29 beat Forte Biosciences' score of 0.80 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, ERAS or FBRX?

Erasca is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.95 N/A Forte Biosciences N/A N/A -$69.38M -$4.65 N/A

Is ERAS or FBRX more profitable?

Erasca's return on equity of -38.43% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -38.43% -32.05% Forte Biosciences N/A -94.82% -77.68%

Does the media refer more to ERAS or FBRX?

In the previous week, Erasca had 5 more articles in the media than Forte Biosciences. MarketBeat recorded 13 mentions for Erasca and 8 mentions for Forte Biosciences. Erasca's average media sentiment score of 1.19 beat Forte Biosciences' score of 0.80 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Forte Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Forte Biosciences (FBRX) Competitors

$76.99 0.00 (0.00%)

As of 08/27/2026

Compare

FBRX vs. COGT, MIRM, TVTX, KNSA, and ERAS

Should you buy Forte Biosciences stock or one of its competitors? Forte Biosciences's main competitors and comparable companies include Cogent Biosciences (COGT), Mirum Pharmaceuticals (MIRM), Travere Therapeutics (TVTX), Kiniksa Pharmaceuticals International (KNSA), and Erasca (ERAS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Forte Biosciences compare to Cogent Biosciences?

Forte Biosciences (NASDAQ:FBRX) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Forte Biosciences is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

Forte Biosciences has a beta of 2.62, indicating that its stock price is 162% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

In the previous week, Cogent Biosciences had 3 more articles in the media than Forte Biosciences. MarketBeat recorded 11 mentions for Cogent Biosciences and 8 mentions for Forte Biosciences. Cogent Biosciences' average media sentiment score of 1.27 beat Forte Biosciences' score of 0.80 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forte Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Forte Biosciences presently has a consensus price target of $71.67, indicating a potential downside of 6.91%. Cogent Biosciences has a consensus price target of $49.40, indicating a potential upside of 42.49%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cogent Biosciences is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

Cogent Biosciences' return on equity of -84.47% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-94.82%	-77.68%
Cogent Biosciences	N/A	-84.47%	-47.72%

77.6% of Forte Biosciences shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Cogent Biosciences beats Forte Biosciences on 11 of the 14 factors compared between the two stocks.

How does Forte Biosciences compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Forte Biosciences (NASDAQ:FBRX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

Mirum Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.62, indicating that its stock price is 162% more volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.14	-$23.36M	-$14.55	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A

77.6% of Forte Biosciences shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 4.4% of Forte Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Forte Biosciences has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Mirum Pharmaceuticals' return on equity of -36.28% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Forte Biosciences	N/A	-94.82%	-77.68%

Mirum Pharmaceuticals presently has a consensus price target of $137.31, suggesting a potential upside of 40.89%. Forte Biosciences has a consensus price target of $71.67, suggesting a potential downside of 6.91%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Mirum Pharmaceuticals had 10 more articles in the media than Forte Biosciences. MarketBeat recorded 18 mentions for Mirum Pharmaceuticals and 8 mentions for Forte Biosciences. Mirum Pharmaceuticals' average media sentiment score of 1.24 beat Forte Biosciences' score of 0.80 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	11 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Forte Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mirum Pharmaceuticals beats Forte Biosciences on 12 of the 16 factors compared between the two stocks.

How does Forte Biosciences compare to Travere Therapeutics?

Forte Biosciences (NASDAQ:FBRX) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Travere Therapeutics has higher revenue and earnings than Forte Biosciences. Travere Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A
Travere Therapeutics	$490.73M	12.61	-$25.55M	-$0.46	N/A

Forte Biosciences presently has a consensus target price of $71.67, suggesting a potential downside of 6.91%. Travere Therapeutics has a consensus target price of $61.67, suggesting a potential downside of 6.10%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Travere Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

77.6% of Forte Biosciences shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by company insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Forte Biosciences and Forte Biosciences both had 8 articles in the media. Travere Therapeutics' average media sentiment score of 1.29 beat Forte Biosciences' score of 0.80 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forte Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Forte Biosciences has a beta of 2.62, suggesting that its stock price is 162% more volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

Forte Biosciences has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Travere Therapeutics' return on equity of -55.15% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-94.82%	-77.68%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

Summary

Travere Therapeutics beats Forte Biosciences on 10 of the 14 factors compared between the two stocks.

How does Forte Biosciences compare to Kiniksa Pharmaceuticals International?

Forte Biosciences (NASDAQ:FBRX) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Forte Biosciences currently has a consensus price target of $71.67, suggesting a potential downside of 6.91%. Kiniksa Pharmaceuticals International has a consensus price target of $87.38, suggesting a potential upside of 11.90%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher probable upside, analysts plainly believe Kiniksa Pharmaceuticals International is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Forte Biosciences' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-94.82%	-77.68%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

Kiniksa Pharmaceuticals International has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A
Kiniksa Pharmaceuticals International	$677.56M	8.99	$59.01M	$0.97	80.49

Forte Biosciences has a beta of 2.62, meaning that its share price is 162% more volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.05, meaning that its share price is 95% less volatile than the broader market.

In the previous week, Forte Biosciences had 7 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 8 mentions for Forte Biosciences and 1 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.87 beat Forte Biosciences' score of 0.80 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Overall Sentiment
Forte Biosciences	Positive
Kiniksa Pharmaceuticals International	Very Positive

77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Kiniksa Pharmaceuticals International beats Forte Biosciences on 12 of the 15 factors compared between the two stocks.

How does Forte Biosciences compare to Erasca?

Erasca (NASDAQ:ERAS) and Forte Biosciences (NASDAQ:FBRX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Erasca's return on equity of -38.43% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-38.43%	-32.05%
Forte Biosciences	N/A	-94.82%	-77.68%

67.8% of Erasca shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 14.2% of Erasca shares are held by insiders. Comparatively, 4.4% of Forte Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Erasca currently has a consensus target price of $22.09, indicating a potential upside of 22.52%. Forte Biosciences has a consensus target price of $71.67, indicating a potential downside of 6.91%. Given Erasca's stronger consensus rating and higher possible upside, research analysts plainly believe Erasca is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Erasca had 5 more articles in the media than Forte Biosciences. MarketBeat recorded 13 mentions for Erasca and 8 mentions for Forte Biosciences. Erasca's average media sentiment score of 1.19 beat Forte Biosciences' score of 0.80 indicating that Erasca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Forte Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Erasca is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A

Erasca has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.62, indicating that its stock price is 162% more volatile than the broader market.

Summary

Erasca beats Forte Biosciences on 9 of the 13 factors compared between the two stocks.

Get Forte Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBRX vs. The Competition

Export

Metric	Forte Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.63B	$3.94B	$7.21B	$12.91B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-16.56	11.62	273.16	25.45
Price / Sales	N/A	1,359.72	625.22	90.88
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	8.89	16.53	12.98	6.14
Net Income	-$69.38M	-$22.80M	$3.48B	$348.86M
7 Day Performance	0.09%	-0.31%	0.13%	-0.80%
1 Month Performance	0.01%	9.80%	7.08%	4.13%
1 Year Performance	599.91%	55.66%	24.67%	15.17%

Forte Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBRX Forte Biosciences	1.393 of 5 stars	$76.99 flat	$71.67 -6.9%	N/A	$1.63B	N/A	N/A	5	News Coverage Analyst Upgrade
COGT Cogent Biosciences	2.8225 of 5 stars	$36.80 +1.6%	$49.40 +34.2%	+187.0%	$6.39B	N/A	N/A	80	Positive News
MIRM Mirum Pharmaceuticals	3.5447 of 5 stars	$98.08 +1.4%	$137.33 +40.0%	+31.9%	$6.37B	$521.31M	N/A	140	News Coverage Positive News Analyst Forecast
TVTX Travere Therapeutics	1.6834 of 5 stars	$67.01 +2.7%	$61.67 -8.0%	+275.3%	$6.32B	$490.73M	N/A	460	Positive News
KNSA Kiniksa Pharmaceuticals International	3.8725 of 5 stars	$80.20 +1.0%	$87.38 +8.9%	+133.1%	$6.26B	$677.56M	82.68	220	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBRX) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Forte Biosciences (FBRX) Competitors

FBRX vs. COGT, MIRM, TVTX, KNSA, and ERAS

How does Forte Biosciences compare to Cogent Biosciences?

Summary

How does Forte Biosciences compare to Mirum Pharmaceuticals?

Summary

How does Forte Biosciences compare to Travere Therapeutics?

Summary

How does Forte Biosciences compare to Kiniksa Pharmaceuticals International?

Summary

How does Forte Biosciences compare to Erasca?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX vs. The Competition

Forte Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Forte Biosciences (FBRX) Competitors

FBRX vs. COGT, MIRM, TVTX, KNSA, and ERAS

How does Forte Biosciences compare to Cogent Biosciences?

Which has stronger earnings and valuation, FBRX or COGT?

Which has more volatility & risk, FBRX or COGT?

Does the media prefer FBRX or COGT?

Do analysts recommend FBRX or COGT?

Is FBRX or COGT more profitable?

Do institutionals & insiders believe in FBRX or COGT?

Summary

How does Forte Biosciences compare to Mirum Pharmaceuticals?

Which has more volatility & risk, MIRM or FBRX?

Which has higher valuation & earnings, MIRM or FBRX?

Do institutionals and insiders hold more shares of MIRM or FBRX?

Is MIRM or FBRX more profitable?

Do analysts rate MIRM or FBRX?

Does the media favor MIRM or FBRX?

Summary

How does Forte Biosciences compare to Travere Therapeutics?

Which has preferable valuation and earnings, FBRX or TVTX?

Do analysts prefer FBRX or TVTX?

Do institutionals & insiders hold more shares of FBRX or TVTX?

Does the media favor FBRX or TVTX?

Which has more volatility & risk, FBRX or TVTX?

Is FBRX or TVTX more profitable?

Summary

How does Forte Biosciences compare to Kiniksa Pharmaceuticals International?

Do analysts recommend FBRX or KNSA?

Is FBRX or KNSA more profitable?

Which has preferable earnings and valuation, FBRX or KNSA?

Which has more risk & volatility, FBRX or KNSA?

Does the media prefer FBRX or KNSA?

Do insiders & institutionals hold more shares of FBRX or KNSA?

Summary

How does Forte Biosciences compare to Erasca?

Is ERAS or FBRX more profitable?

Do insiders and institutionals hold more shares of ERAS or FBRX?

Do analysts recommend ERAS or FBRX?

Does the media refer more to ERAS or FBRX?

Which has higher earnings & valuation, ERAS or FBRX?

Which has more volatility & risk, ERAS or FBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX vs. The Competition

Forte Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools